Research output per year
Research output per year
Personal profile
Research interests
I am interested in the role of fungal allergens in allergic rhinitis and asthma, particualrly with respect to the production of nasal cytokines. I am also interested in new treatment modalities for chronic urticaria as well as other atopic diseases.
Clinical interests
Asthma, urticaria, hives, children with asthma, infectious diseases, allergies, allergic diseases, immunological diseases, allergic reactivity, allergic conjunctivitis, articulation of asthma, eosinophilia, usage of antibodies, immunochemistry, lymphocyte activation, development of immunities, clinical immunology, chronic fatigue syndrome, fungal allergies, environmental control for allergies
Fingerprint
Dive into the research topics where James Wedner is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Optimization of care for patients with hereditary angioedema living in rural areas
Riedl, M. A., Johnston, D. T., Anderson, J., Meadows, J. A., Soteres, D., LeBlanc, S. B., Wedner, H. J. & Lang, D. M., May 1 2022, In: Annals of Allergy, Asthma and Immunology. 128, 5, p. 526-533 8 p.Research output: Contribution to journal › Review article › peer-review
Open Access -
Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study
on behalf of the HELP Study Investigators, Apr 2021, In: Allergy: European Journal of Allergy and Clinical Immunology. 76, 4, p. 1188-1198 11 p.Research output: Contribution to journal › Article › peer-review
Open Access12 Scopus citations -
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
SYNAPSE study investigators, Oct 2021, In: The Lancet Respiratory Medicine. 9, 10, p. 1141-1153 13 p.Research output: Contribution to journal › Article › peer-review
71 Scopus citations -
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial
Zuraw, B., Lumry, W. R., Johnston, D. T., Aygören-Pürsün, E., Banerji, A., Bernstein, J. A., Christiansen, S. C., Jacobs, J. S., Sitz, K. V., Gower, R. G., Gagnon, R., Wedner, H. J., Kinaciyan, T., Hakl, R., Hanzlíková, J., Anderson, J. T., McNeil, D. L., Fritz, S. B., Yang, W. H., Tachdjian, R. & 16 others, , Jul 2021, In: Journal of Allergy and Clinical Immunology. 148, 1, p. 164-172.e9Research output: Contribution to journal › Article › peer-review
Open Access38 Scopus citations -
Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)
Wedner, H. J., Aygören-Pürsün, E., Bernstein, J., Craig, T., Gower, R., Jacobs, J. S., Johnston, D. T., Lumry, W. R., Zuraw, B. L., Best, J. M., Iocca, H. A., Murray, S. C., Desai, B., Nagy, E., Sheridan, W. P. & Kiani-Alikhan, S., Jun 2021, In: Journal of Allergy and Clinical Immunology: In Practice. 9, 6, p. 2305-2314.e4Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations